2.08
-0.12(-5.45%)
Currency In USD
| Previous Close | 2.2 |
| Open | 2.19 |
| Day High | 2.19 |
| Day Low | 2.07 |
| 52-Week High | 9.53 |
| 52-Week Low | 1.11 |
| Volume | 198,708 |
| Average Volume | 598,401 |
| Market Cap | 40.54M |
| PE | -0.99 |
| EPS | -2.1 |
| Moving Average 50 Days | 2.19 |
| Moving Average 200 Days | 2.35 |
| Change | -0.12 |
If you invested $1000 in Annovis Bio, Inc. (ANVS) since IPO date, it would be worth $216.89 as of October 31, 2025 at a share price of $2.08. Whereas If you bought $1000 worth of Annovis Bio, Inc. (ANVS) shares 3 years ago, it would be worth $165.74 as of October 31, 2025 at a share price of $2.08.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Annovis Announces $3.4 Million Registered Direct Offering of Common Stock Priced At-the-Market under the NYSE Rules
GlobeNewswire Inc.
Oct 27, 2025 12:00 PM GMT
MALVERN, Pa., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease
Annovis Announces Closing of $6 Million Registered Direct Offering of Common Stock
GlobeNewswire Inc.
Oct 15, 2025 9:15 PM GMT
MALVERN, Pa., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease
Annovis Announces $6 Million Registered Direct Offering of Common Stock
GlobeNewswire Inc.
Oct 10, 2025 12:31 PM GMT
MALVERN, Pa., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease